Evidence map›Paper›PMID 34148185›Full record

ArticleMedical oncology (Northwood, London, England)2021

ceRNA network development and tumor-infiltrating immune cell analysis in hepatocellular carcinoma.

Li Chen, Weijie Zou, Lei Zhang, Huijuan Shi, Zhi Li, Caifang Ni

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Li Chen *Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, 215006, People's Republic of China.
Weijie Zou *Department of Radiology, The First Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, 215006, People's Republic of China.
Lei Zhang *Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, 215006, People's Republic of China.
Huijuan ShiDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, 215006, People's Republic of China.
Zhi LiDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, 215006, People's Republic of China. lizhisoochow@suda.edu.cn.
Caifang NiDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Jiangsu Province, Suzhou, 215006, People's Republic of China. szncf@suda.edu.cn.ORCID http://orcid.org/0000-0003-2693-367X
Soochow University · CN

Funding

Basic Research Program of Jiangsu Province BK20190177Jiangsu Provincial Medical Innovation Team CXTDB2017006
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is among the primary causes of cancer deaths globally. Despite efforts to understand liver cancer, its high morbidity and mortality remain high. Herein, we constructed two nomograms based on competing endogenous RNA (ceRNA) networks and invading immune cells to describe the molecular mechanisms along with the clinical prognosis of HCC patients. RNA maps of tumors and normal samples were downloaded from The Cancer Genome Atlas database. HTseq counts and fragments per megapons per thousand bases were read from 421 samples, including 371 tumor samples and 50 normal samples. We established a ceRNA network based on differential gene expression in normal versus tumor subjects. CIBERSORT was employed to differentiate 22 immune cell types according to tumor transcriptomes. Kaplan-Meier along with Cox proportional hazard analyses were employed to determine the prognosis-linked factors. Nomograms were constructed based on prognostic immune cells and ceRNAs. We employed Receiver operating characteristic (ROC) and calibration curve analyses to estimate these nomogram. The difference analysis found 2028 messenger RNAs (mRNAs), 128 micro RNAs (miRNAs), and 136 long non-coding RNAs (lncRNAs) to be significantly differentially expressed in tumor samples relative to normal samples. We set up a ceRNA network containing 21 protein-coding mRNAs, 12 miRNAs, and 3 lncRNAs. In Kaplan-Meier analysis, 21 of the 36 ceRNAs were considered significant. Of the 22 cell types, resting dendritic cell levels were markedly different in tumor samples versus normal controls. Calibration and ROC curve analysis of the ceRNA network, as well as immune infiltration of tumor showed restful accuracy (3-year survival area under curve (AUC): 0.691, 5-year survival AUC: 0.700; 3-year survival AUC: 0.674, 5-year survival AUC: 0.694). Our data suggest that Tregs, CD4 T cells, mast cells, SNHG1, HMMR and hsa-miR-421 are associated with HCC based on ceRNA immune cells co-expression patterns. On the basis of ceRNA network modeling and immune cell infiltration analysis, our study offers an effective bioinformatics strategy for studying HCC molecular mechanisms and prognosis.

Indexed as

Carcinoma, HepatocellularGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansImmunity, CellularLiver NeoplasmsMicroRNAsNomogramsRNARNA, Long NoncodingRNA, MessengerSurvival AnalysisMicroRNAsRNARNA, Long NoncodingRNA, MessengerceRNA networkHCCImmune infiltrationNomogramPrognosis

Identifiers

PMID34148185
OpenAlexW3159068698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.